UBS Maintains Buy on BrightSpring Health, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
UBS analyst A.J. Rice has maintained a Buy rating on BrightSpring Health (NASDAQ:BTSG) and raised the price target from $16 to $20.
October 30, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst A.J. Rice has maintained a Buy rating on BrightSpring Health and increased the price target from $16 to $20, indicating a positive outlook.
The increase in the price target from $16 to $20 by UBS suggests a positive outlook for BrightSpring Health, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100